LONDON -- Shares in Reckitt Benckiser (LSE: RB ) (NASDAQOTH: RBGLY ) lifted this morning following the group's positive fourth-quarter and full-year earnings release, with management declaring that its strategy is "well on track."
The earnings release also reported a three-year collaboration agreement with U.S. biopharmaceutical company Bristol-Myers Squibb, for a number of market-leading over-the-counter consumer health-care brands in Latin America, including Brazil and Mexico.
The arrangement includes personnel, supply contracts, and an option to acquire legal title to the related intellectual property at the end of the collaboration period for a multiple of earnings.
Reckitt saw net revenue for Q4 hit 2.48 billion pounds, up 2% on actual exchange rates and 6% on constant rates. The full-year figure was 9.58 billion pounds, up 1% actual and 4% constant.
Like-for-like growth increased 7% in the fourth quarter, and 5% across the full year -- well ahead of its market growth, driven by emerging-market areas and Europe/North America (ENA). Additionally, the company's sales were boosted by "higher incidences of cold and flu."
Health and hygiene led Reckitt's growth, with a broad range of products, including Durex, Gaviscon, Strepsils, Dettol, Lysol, Harpic, and Finish. Chief Executive Officer Rakesh Kapoor commented, "We are laying the foundations for RB to succeed in a world where health and hygiene play an increasingly important role in terms of both economic and social development."
We enhanced our focus on our 16 power markets, many of which are in the emerging-market areas that now represent 44% of our core net revenue. I am very pleased that our 2012 achievements demonstrate the strength of this strategy and its ability to create sustainable value for all of our stakeholders.
While much has yet to be done and markets remain challenging, we approach 2013 with the confidence that we have the right strategic focus, the right organization and culture, and with the right innovation platforms. We are particularly excited by our entry into the vitamins, minerals, and supplements market with the acquisition of Schiff. We are supporting our brands with more and better-quality brand equity investment to deliver further growth in an increasingly competitive consumer environment.
We remain committed to our goal of net revenue growth on average +200bps per annum above our market growth, and moderate operating margin expansion (ex RBP). For 2013, we are targeting net revenue growth of +5-6% including acquisitions and disposals announced to date. Given the early achievement of cost savings in 2012, we expect to maintain operating margins in 2013. These targets exclude RBP.
This will allow us to further accelerate the shape of our core business in line with our strategy. We are now setting the target of health and hygiene categories to become 72%, and our emerging market areas to become 50%, of our core business net revenue by 2015. This is a year earlier than previously targeted.
It's not surprising to see Reckitt focus on emerging markets, after many of its FTSE peers -- including Unilever and Diageo -- have released similar statements in recent weeks. It's positive news for shareholders, too, as the entry into new markets can drive significant growth.
If you're looking to capitalize on the market's positive start, then our analysts have picked out a share that they believe could help. "The Motley Fool's Top Income Share for 2013" offers a 5.7% income, and might be worth 850 pence versus around 700 pence now. Simply click here to download the report now.
Or, if you're looking for a company that should soar in price, our team members have also pinpointed their favorite growth share and produced another free report in which they evaluate its finances and risks, and its growth prospects going forward. Click here to get your copy delivered to your inbox immediately.